NO20011759L - Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi - Google Patents

Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi

Info

Publication number
NO20011759L
NO20011759L NO20011759A NO20011759A NO20011759L NO 20011759 L NO20011759 L NO 20011759L NO 20011759 A NO20011759 A NO 20011759A NO 20011759 A NO20011759 A NO 20011759A NO 20011759 L NO20011759 L NO 20011759L
Authority
NO
Norway
Prior art keywords
tumor
flt4
vegfr
target material
imaging
Prior art date
Application number
NO20011759A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011759D0 (no
Inventor
Kari Alitalo
Arja Kaipainen
Reija Valltola
Lotta Jussila
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/169,079 external-priority patent/US6824777B1/en
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20011759D0 publication Critical patent/NO20011759D0/no
Publication of NO20011759L publication Critical patent/NO20011759L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20011759A 1998-10-09 2001-04-06 Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi NO20011759L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/169,079 US6824777B1 (en) 1992-10-09 1998-10-09 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en) 1998-10-09 1999-10-08 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (2)

Publication Number Publication Date
NO20011759D0 NO20011759D0 (no) 2001-04-06
NO20011759L true NO20011759L (no) 2001-06-11

Family

ID=22614189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011759A NO20011759L (no) 1998-10-09 2001-04-06 Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi

Country Status (13)

Country Link
US (4) US8444957B2 (enExample)
EP (1) EP1119371B1 (enExample)
JP (5) JP4841724B2 (enExample)
CN (1) CN100340291C (enExample)
AT (1) ATE489108T1 (enExample)
AU (2) AU774266B2 (enExample)
CA (1) CA2345276C (enExample)
DE (1) DE69942981D1 (enExample)
DK (1) DK1119371T3 (enExample)
ES (1) ES2357406T3 (enExample)
NO (1) NO20011759L (enExample)
NZ (2) NZ511408A (enExample)
WO (1) WO2000021560A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6451764B1 (en) 1995-09-08 2002-09-17 Genentech, Inc. VEGF-related protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CN100340291C (zh) * 1998-10-09 2007-10-03 路德维格癌症研究院 F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
ATE377081T1 (de) 2000-02-25 2007-11-15 Ludwig Inst Cancer Res Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
CN1211126C (zh) 2000-08-04 2005-07-20 人体基因组科学有限公司 血管内皮生长因子2
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CA2452058A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
US8305579B2 (en) * 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US9677125B2 (en) 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2911681A1 (en) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
EP0171407B1 (en) * 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
JP2736255B2 (ja) * 1987-03-11 1998-04-02 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー イムノグロブリン結合体
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198359A (en) * 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2
WO1990014425A1 (en) 1989-05-22 1990-11-29 Zymogenetics, Inc. PDGF α-RECEPTOR
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DE69231128T2 (de) 1991-01-31 2001-02-15 Cor Therapeutics, Inc. Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
WO1992014748A1 (en) 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
US5231001A (en) * 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
HUT69792A (en) 1992-01-09 1995-09-28 Helsinki University Holding Lt Tie, a nocel endothelial cell receptor tyrosine kinase
WO1993015201A1 (en) 1992-01-22 1993-08-05 New England Deaconess Hospital Novel protein tyrosine kinases
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DK0807124T3 (da) * 1994-06-09 2006-08-28 Licentia Oy Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6451764B1 (en) * 1995-09-08 2002-09-17 Genentech, Inc. VEGF-related protein
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
EP2107109B1 (en) 1996-08-23 2012-06-20 Vegenics Pty Ltd Recombinant vascular endothelial cell growth factor D (VEGF-D)
US7947472B2 (en) 1997-12-24 2011-05-24 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor D
CN100340291C (zh) * 1998-10-09 2007-10-03 路德维格癌症研究院 F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
KR101681886B1 (ko) 2015-04-06 2016-12-12 서울대학교산학협력단 지르코니아 결합능을 가지는 펩타이드

Also Published As

Publication number Publication date
WO2000021560A9 (en) 2000-09-21
CA2345276A1 (en) 2000-04-20
JP2012019790A (ja) 2012-02-02
DE69942981D1 (de) 2011-01-05
EP1119371B1 (en) 2010-11-24
JP2013209382A (ja) 2013-10-10
CA2345276C (en) 2011-03-29
JP2002527404A (ja) 2002-08-27
JP2015157829A (ja) 2015-09-03
US20160184405A1 (en) 2016-06-30
NZ511408A (en) 2004-04-30
CN100340291C (zh) 2007-10-03
CN1329504A (zh) 2002-01-02
AU774266B2 (en) 2004-06-24
EP1119371A1 (en) 2001-08-01
NZ529063A (en) 2005-07-29
AU2004208675A1 (en) 2004-09-30
JP2011121957A (ja) 2011-06-23
ES2357406T3 (es) 2011-04-26
AU1312100A (en) 2000-05-01
NO20011759D0 (no) 2001-04-06
JP4841724B2 (ja) 2011-12-21
WO2000021560A1 (en) 2000-04-20
US8444957B2 (en) 2013-05-21
ATE489108T1 (de) 2010-12-15
JP5784310B2 (ja) 2015-09-24
US20100278736A1 (en) 2010-11-04
JP5642637B2 (ja) 2014-12-17
AU2004208675B2 (en) 2006-03-02
US20140072511A1 (en) 2014-03-13
US20150158928A1 (en) 2015-06-11
DK1119371T3 (da) 2011-03-07

Similar Documents

Publication Publication Date Title
NO20011759D0 (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
NO20033285L (no) FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
EP1141286A4 (en) Cytokine receptor chain
GB9811260D0 (en) Novel compounds
GB9820003D0 (en) Novel compounds
GB9809683D0 (en) Novel compounds
GB9810285D0 (en) Novel compounds
GB9812440D0 (en) Novel compounds
GB9812163D0 (en) Novel compounds
DK1082435T3 (da) Proteiner og gener fra Moraxella catarrhalis, antigener, antistoffer og anvendelser
GB9918208D0 (en) Novel compounds
GB0025170D0 (en) Novel compounds
GB9918302D0 (en) Novel compounds
DE60019614D1 (de) Moraxella catarrhalis antigen basb117
GB0025169D0 (en) Novel compounds
DE60019613D1 (de) Moraxella catarrhalis antigen basb120
GB9914945D0 (en) Novel compounds
BR1100558A (pt) famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer.
MX9605355A (es) El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer.
AU1383901A (en) Novel compounds